Revenue
2010
2011
2012
2013
2014
2015
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics, Inc. (ENDV)
Price$0.0001Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2014
2015
2017
2018
2019
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10,043 | $140,242 | $135,355 | $73,105 | $165,796 | $310,164 | $83,263 | — | — | $4,265 | $24,192 | $22,896 | $30,581 | $45,544 | $51,199 |
| Gross profit | $3,334 | $132,402 | $125,365 | $58,120 | $100,427 | $216,779 | $70,333 | — | — | $2,103 | $8,707 | $8,903 | — | — | — |
| Gross margin | 33.20% | 94.41% | 92.62% | 79.50% | 60.57% | 69.89% | 84.47% | — | — | 49.31% | 35.99% | 38.88% | — | — | — |
| Research & development | — | — | — | $0 | $3,283 | $153,126 | $274,265 | $115,159 | $0 | — | — | — | — | — | — |
| Operating expenses | $1.6M | $3.1M | $3.4M | $2.3M | $3.0M | $4.0M | $4.2M | $4.6M | $5.4M | $2.6M | $2.2M | $2.4M | $1.8M | $141,068 | $129,185 |
| Operating income | −$1.6M | −$2.9M | −$3.3M | −$2.2M | −$2.9M | −$3.8M | −$4.2M | −$4.6M | −$5.4M | −$2.6M | −$2.2M | −$2.4M | −$1.7M | −$95,524 | −$77,986 |
| Operating margin | −15,532.54% | −2,081.72% | −2,411.69% | −3,045.68% | −1,756.49% | −1,228.08% | −4,995.33% | — | — | −60,132.73% | −9,057.59% | −10,607.65% | −5,697.49% | −209.74% | −152.32% |
| EBITDA | −$941,401 | $8.9M | −$2.6M | −$1.6M | −$2.3M | −$3.2M | −$3.5M | −$4.6M | −$5.4M | −$2.5M | −$2.2M | −$2.4M | −$1.7M | −$94,545 | −$77,022 |
| EBITDA margin | −9,373.70% | 6,313.23% | −1,933.75% | −2,158.61% | −1,363.69% | −1,018.42% | −4,214.41% | — | — | −59,786.35% | −8,992.54% | −10,555.39% | −5,576.39% | −207.59% | −150.44% |
| Net income | −$2.8M | $6.9M | −$18.5M | −$3.1M | −$395,584 | −$17.3M | −$6.4M | −$10.8M | −$5.3M | −$6.8M | −$959,494 | −$2.9M | −$1.9M | −$94,088 | −$69,400 |
| Net profit margin | −27,853.20% | 4,937.60% | −13,649.17% | −4,247.17% | −238.60% | −5,582.37% | −7,729.53% | — | — | −158,633.90% | −3,966.16% | −12,634.50% | −6,260.59% | −206.59% | −135.55% |
| Basic EPSper basic share | $0.00 | $0.03 | -$0.13 | -$0.05 | -$0.03 | -$24.83 | -$0.02 | -$0.04 | -$0.05 | -$0.07 | -$0.03 | -$3.96 | -$0.04 | -$0.02 | -$0.02 |
| Diluted EPSper diluted share | $0.00 | $0.01 | -$0.13 | -$0.05 | -$0.03 | -$24.83 | -$0.02 | -$0.04 | -$0.05 | -$0.07 | -$0.03 | -$3.96 | -$0.04 | -$0.02 | -$0.02 |
Owners
Reported shareholders